[미국특허]
Intravaginal drug delivery devices for the administration of an antimicrobial agent
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-006/06
A61F-006/14
출원번호
US-0107997
(2002-03-27)
우선권정보
IE-S2001/0307 (2001-03-27)
발명자
/ 주소
Malcolm, Karl
Woolfson, David
Elliott, Grant
Shephard, Martin
출원인 / 주소
Galen (Chemicals) Limited
대리인 / 주소
Fitzpatrick, Cella, Harper &
인용정보
피인용 횟수 :
77인용 특허 :
29
초록
An intravaginal antimicrobial drug delivery device is disclosed having an antimicrobial agent dispersed throughout a biocompatible elastomeric system. Also disclosed is a method of making the antimicrobial drug delivery device.
대표청구항▼
1. An intravaginal antimicrobial drug delivery device comprising:a therapeutically effective amount of at least one antimicrobial agent dispersed throughout a biocompatible elastomeric system that forms said delivery device, wherein between 5 mg and 600 mg of said at least one antimicrobial agent is
1. An intravaginal antimicrobial drug delivery device comprising:a therapeutically effective amount of at least one antimicrobial agent dispersed throughout a biocompatible elastomeric system that forms said delivery device, wherein between 5 mg and 600 mg of said at least one antimicrobial agent is released during an initial 24 hour period of use, and wherein said delivery device consists essentially of a ring. 2. The intravaginal drug delivery device of claim 1, wherein said biocompatible elastomeric system is hydrophobic.3. The intravaginal drug delivery device of claim 1, wherein said antimicrobial agent is dispersed homogeneously.4. The intravaginal drug delivery device of claim 1, wherein the ring has a cross-sectional diameter in a range of about 2.5 to about 15 mm.5. The intravaginal drug delivery device of claim 4, wherein the ring has an outer diameter in a range of about 40 to about 65 mm.6. The intravaginal drug delivery device of claim 1, wherein said antimicrobial agent is released at a substantially first order release rate during said initial twenty four hour period of use.7. The intravaginal drug delivery device of claim 6, wherein said antimicrobial agent is released at a substantially zero order release rate over at least a 3 day period of time, after said initial 24 hour period of use.8. The intravaginal drug delivery device of claim 1, wherein the solubility in distilled water of said antimicrobial agent is not less than 1 μg/100 ml at 20° C.9. The intravaginal drug delivery device of claim 2, wherein said hydrophobic elastomeric system is a silicone polymer.10. The intravaginal drug delivery device of claim 1, wherein between 5 mg and 250 mg of said at least one antimicrobial agent is released during said initial 24 hour period of use.11. The intravaginal drug delivery device of claim 7, wherein between 0.25 mg and 400 mg of said at least one antimicrobial agent is released per day, for at least said 3 days following said initial 24 hour period of use.12. The intravaginal drug delivery device of claim 1, wherein said antimicrobial agent is selected from the group consisting of Metronidazole, Acyclovir, Clotrimazole, Fluconazole, Terconazole, Azithromycin, Erythromycin, Doxycycline, Tetracycline, Minocycline, Clindamycin, Famcyclovir, Valacyclovir, Clarithromycin, a prodrug or salt thereof and combinations thereof.13. The intravaginal drug delivery device of claim 1, further comprising one or more other pharmaceutically compatible agents.14. The intravaginal drug delivery device of claim 13, wherein said one or more pharmaceutically compatible agents are selected from the group consisting of pharmaceutical excipients, pharmacologically active agents and combinations thereof.15. The intravaginal drug delivery device of claim 14, wherein said pharmaceutical excipients are selected from the group consisting of buffers, polymers, fillers and combinations thereof.16. The intravaginal drug delivery device of claim 14, wherein said pharmaceutical excipient is selected from the group consisting of polyvinylpyrrolidone, modified cellulose ethers, microcrystalline cellulose, polyacrylic acid, carbomer, alginic acid, carrageenan, cyclodextrins, dextrin, guar gum, gelatin and xanthan gum, monosaccharides and disaccharides.17. The intravaginal drug delivery device of claim 14, wherein said pharmacologically active agent is selected from the group consisting of local anaesthetics, local analgesics and combinations thereof.18. The intravaginal drug delivery device of claim 1, wherein a particle size distribution of the antimicrobial agent is 90% particles of less than 200 microns and 50% particles of less than 50 microns.19. An intravaginal drug delivery device comprising:a therapeutically effective amount of Metronidazole, a prodrug or salt thereof, dispersed throughout a biocompatible elastomeric system that forms said drug delivery device, wherein between 5 mg and 600 mg of said Metronidazole is released during an initial 24 hour period of use, and wherein said delivery device consists essentially of a ring. 20. The intravaginal drug delivery device of claim 19, wherein said biocompatible elastomeric system is hydrophobic.21. The intravaginal drug delivery device of claim 19, wherein said antimicrobial agent is dispersed homogeneously.22. The intravaginal drug delivery device of claim 19, wherein said ring has a cross-sectional diameter of about 6-14 mm.23. The intravaginal drug delivery device of claim 22, wherein said ring has an outer diameter of about 50-60 mm.24. The intravaginal drug delivery device of claim 19, wherein said Metronidazole, prodrug or salt thereof, is released at a substantially first order rate of about 5 to about 250 mg during said initial 24 hours period of use.25. The intravaginal drug delivery device of claim 24, wherein said Metronidazole, prodrug or salt thereof is released at a substantially zero order rate of about 3 to about 175 mg per day over a period for at least 3 days, after the initial 24 hour period of use.26. The intravaginal drug delivery device of claim 19, wherein said Metronidazole, prodrug or salt thereof, is present in an amount in a range of about 0.5 to about 80 weight percent of said device.27. The intravaginal drug delivery device of claim 20, wherein said hydrophobic elastomeric system is a silicone polymer.28. The intravaginal drug delivery device of claim 27, wherein said silicone polymer is crosslinked.29. The intravaginal drug delivery device of claim 19, further comprising a release enhancing excipient.30. The intravaginal drug delivery device of claim 29, wherein said release enhancing excipient is selected from the group consisting of polyvinylpyrrolidone, modified cellulose ethers, microcrystalline cellulose, polyacrylic acid, carbomer, alginic acid, carrageenan, cyclodextrins, dextrin, guar gum, gelatin, xanthan gum, monosaccharides and disaccharides.31. The intravaginal drug delivery device of claim 19, wherein a particle size distribution of the Metronidazole, prodrug or salt thereof is 90% particles of less than 200 microns and 50% particles of less than 50 microns.32. The method of manufacturing an intravaginal antimicrobial drug delivery device comprising the steps:(a) mixing a biocompatible elastomer with at least one antimicrobial agent in at least a therapeutically effective amount; and (b) curing said mixture in a shape of said intravaginal drug delivery devices, wherein said delivery device consists essentially of a ring. 33. The method according to claim 32, wherein the biocompatible elastomer is hydrophobic.34. The method according to claim 33, wherein said biocompatible hydrophobic elastomer is a silicone polymer.35. The method according to claim 32, wherein the mixture of biocompatible elastomer and antimicrobial agent includes a crosslinking agent.36. The method according to claim 32, wherein said antimicrobial agent is selected from the group consisting of Metronidazole, Acyclovir, Clotrimazole, Fluconazole, Terconazole, Azithromycin, Erythromycin, Doxycycline, Tetracycline, Minocycline, Clindamycin, Fanicyclovir, Valacyclovir, Clarithromycin, a prodrug or salt thereof and combinations thereof.37. The method according to claim 32, wherein said antimicrobial agent is Metronidazole, a produg or salt thereof.38. The method according to claim 32, wherein the mixture of biocompatible hydrophobic elastomer and antimicrobial agent includes a release enhancing excipient.39. The method according to claim 38, wherein said release enhancing excipient is selected from the group consisting of polyvinylpyrrolidone, modified cellulose ethers, microcrystalline cellulose, polyacrylic acid, carbomer, alginic acid, carrageenan, cyclodextrins, dextrin, guar gum, gelatin, xanthan gum, monosaccharides and disaccharides.40. An intravaginal antimicrobial drug delivery device comprising:a therapeutically effective amount of at least one antimicrobial agent dispersed throughout a biocompatible elastomeric system that forms said delivery device, wherein said antimicrobial agent is released at a substantially first order release rate during an initial twenty four hour period of use. 41. An intravaginal antimicrobial drug delivery device comprising:a therapeutically effective amount of at least one antimicrobial agent dispersed throughout a biocompatible elastomeric system that forms said delivery device, wherein the solubility in distilled water of said antimicrobial agent is not less than 1 μg/100 ml at 20° C. 42. An intravaginal antimicrobial drug delivery device comprising:a therapeutically effective amount of at least one antimicrobial agent dispersed throughout a biocompatible elastomeric system that forms said delivery device, wherein a particle size distribution of the antimicrobial agent is 90% particles of less than 200 microns and 50% particles of less than 50 microns.
Heeres Jan (Vosselaar BEX) Backx Leo J. J. (Arendonk BEX) Mostmans Joseph H. (Antwerp BEX), 1-(1,3-Dioxolan-2-ylmethyl)-1H-1,2,4-triazoles and compositions.
Johansson Rolf A. (Huddinge SEX) Moses Pinchas (Satsjo-Boo SEX) Nilvebrant Lisbeth (Bromma SEX) Sparf Bengt Å. (Trngsund SEX), 3,3-diphenylpropylamines, their use and preparation.
Rajadhyaksha Vithal J. (27436 Esqina Mission Viejo CA 92691), Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active a.
Hale Ron L. (Woodside CA) Lu Amy (Los Altos CA) Solas Dennis (San Francisco CA) Selick Harold E. (Belmont CA) Oldenburg Kevin R. (Fremont CA) Zaffaroni Alejandro C. (Atherton CA), Compositions and methods for enhanced drug delivery.
Cohen Robert S. (New York NY) Pierce James M. (Coral Gables FL) Kinsey William H. (Coral Gables FL), Intra-vaginal device and method for sustained drug release.
Aberg Gunnar (Westborough MA) McCullough John R. (Worcester MA), Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin.
Penkler Lawrence John,ZAX ; De Kock Lueta-Ann,ZAX ; Whittaker Darryl Vanstone,ZAX, Pharmaceutical composition containing acid addition salt of basic drug.
Contente Audrey (New York NY) Rose Bruce F. (Yorba Linda CA) Potter Richard C. (Seeley Lake MT), Vaginal discharge collection device and intravaginal drug delivery system.
Devlin, Brid; Holt, Jonathon Daryll; Brimer, Andrew Nathan; Nuttall, Jeremy Peter; Malcolm, Karl; Fetherston, Susan Margaret; Boyd, Peter John James, Combination therapy intravaginal rings.
Lee, Heejin; Daniel, Karen; Ho Duc, Hong Linh; Cima, Michael J.; Castillo, Mario; Froelich, Steven; Dimitrakov, Jordan; Kim, Grace Y., Intravesical drug delivery device.
Lee, Heejin; Daniel, Karen; Ho Duc, Hong Linh; Cima, Michael J.; Castillo, Mario; Froelich, Steven; Dimitrakov, Jordan; Kim, Grace Y., Intravesical drug delivery device.
Lee, Heejin; Daniel, Karen Danielle; Ho Duc, Hong Linh; Cima, Michael J.; Castillo, Mario; Froelich, Steven; Dimitrakov, Jordan; Kim, Grace Y., Method for intravesical drug delivery.
Tamarkin, Dov; Gazal, Elana; Keynan, Rita; Eini, Meir; Schuz, David, Methods for accelerated return of skin integrity and for the treatment of impetigo.
Tamarkin, Dov; Ziv, Enbal; Hazot, Yohan; Schuz, David, Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.